Camurus Ab · OMXSTO:CAMX
Camurus Ab — Shareholder Meeting (May 2025)
28 slides from Camurus Ab's shareholder meeting presentation, May 27, 2025
Slide 1: Annual General Meeting 2025 CEO presentation
Annual General Meting 2025 CEO presentation 27 May 2025
Slide 2: Forward looking statements
Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-look
Slide 3: Camurus snapshot
Camurus snapshot Rapidly growing Unique FluidCrystal® commercial stage company technology platform Leader in opioid dependence treatment Commercially validated with a broad with Buvidal® and Brixadi® weekly range of applications and monthly depots Advancing late-stage pipeline Strong operational and
Slide 4: Successful 2024 for Camurus
Successful 2024 for Camurus Strong financial development and high profitability Global leadership in opioid dependence treatment High growth of Buvidal® and Brixadi® Registration applications for CAM2029 in acromegaly and advancing studies in GEP-NET and PLD Initiation of clinical study of monthly s
Slide 5: Positive financial development
Positive financial development •Revenues •Profit before tax MSEK MSEK 2 000 1868 600 549 553 1717 400 1 500 200 1 000 956 73 0 601 500 -112 336 -200 -207 106 0 -400 -362 2019 2019 2020 2021 2021 2022 2023 2024 2022 2023 2019 2020 2021 2022 2023 2024 One-time revenue related to Brixadi US approval On
Slide 6: Strategy for continued value creation
Strategy for continued value creation 1 Grow Buvidal/Brixadi sales and expand to new markets 2 Advance R&D pipeline to new approvals and launches 3 Diversify and grow through business development 4 Drive operational excellence and sustainable profitability Camurus’ vision 2027 5x 4 ~50% Sustainable
Slide 7: On track towards Camurus vision 2027 5x
7 On track towards Camurus vision 2027 •Status after 2 of 5 years – end-2024 5x 4 ~50% Five-fold revenue growth Establish commercial Market approvals for Operating margin around 50% (from 2022) infrastructure in the US development programs 5x revenue growth in 5 years US commercial infrastructure Ne
Slide 8: Commercially validated FluidCrystal technology
Commercially validated FluidCrystal® technology Easy and convenient administration Compatible with prefilled syringes and auto-injector pens Rapid onset & long-acting release Scalable manufacturing For peptide and small molecule drugs Strong and updated patent portfolio Injection of liquid formulati
Slide 9: Development of long-acting medications
9 Development of long-acting medications Typical short-acting – Less frequent dosing release profile – Sustained therapeutic exposure Drug blood concentration – Improved treatment compliance Long-acting release – Improved efficacy and/or reduced profile side effects Therapeutic window – More conveni
Slide 10: Broad and diversified product portfolio and pipeline
Broad and diversified product portfolio and pipeline Products on the market Phase 1 Phase 2 Phase 3 Registration Market Buvidal® Opioid dependence EU, AUS, MENA Brixadi® Opioid use disorder1 US Key pipeline programs CAM2029 Acromegaly US, EU CAM2029 Gastroenteropancreatic neuroendocrine tumors CAM20
Slide 11: Buvidal – game changing opioid dependence treatment
11 Buvidal – game changing opioid dependence treatment • Weekly and monthly, subcutaneous buprenorphine for individualized treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents 16 years or over1 1 SmPC Buvidal 11
Slide 12: Buvidal has demonstrated significant benefits to patients and society
Buvidal has demonstrated significant benefits to patients and society Superior treatment outcome and patient satisfaction1-4 Blocks subjective opioid effects from first dose2 Reduces treatment burden and improve quality of life4,5 Decrease risk of diversion, misuse and pediatric exposure6,7 Provides
Slide 13: Global leadership in long-acting treatment of opioid dependence
Global leadership in long-acting treatment of opioid dependence • Improved access and market share • Product sales Buvidal ‒ Buvidal and Brixadi are global leading products in long-acting MSEK opioid dependence treatment1 1654 • Strong growth in Europe, Australia and the MENA region 1500 ‒ Buvidal s
Slide 14: Successful launch of Brixadi in the US
Successful launch of Brixadi in the US • Positive uptake in the US • Brixadi royalties ‒ Launched in September 2023 MSEK 83 ‒ About 80% payer coverage after 6 months 80 74 ‒ ~25% market share of long-acting segment after first full year 2023 on the market, end-20241 2024 58 ‒ Growth slowing down in
Slide 15: Growing evidence base
Growing evidence base Increasing treatment difference between CAM2038 and Key publications in 20241-5 daily standard treatment (SL 1 BPN/NX) in patients with high illicit drug concentrations CAM2038 superior to daily standard treatment in patients using fentanyl Weekly buprenorphine well tolerated a
Slide 16: Patient benefits – Camurus' driving force
16 Patient benefits – Camurus' driving force Marie, Buvidal Will, Buvidal Daniel, Buvidal Antonio, Buvidal Cullan, Buvidal Beny, Buvidal CONFIDENTIAL Nina, Buvidal Santos, Buvidal Mattias, Buvidal
Slide 17: Octreotide SC depot, CAM2029
Octreotide SC depot, CAM2029 Under development for the treatment of three rare disease indications Acromegaly Gastroenteropancreatic neuroendocrine tumors (GEP-NET) Polycystic liver disease (PLD) Designed for enhanced efficacy and improved convenience for patients 17
Slide 18: CAM2029 designed to address key medical needs
CAM2029 designed to address key medical needs Commercially validated FluidCrystal® technology Rapid onset and long-acting octreotide release1 5-fold octreotide bioavailability vs Sandostatin LAR with potential for improved efficacy1-3 State-of-the-art, pre-filled autoinjector pen enabling convenient
Slide 19: Comprehensive CAM2029 clinical program
Comprehensive CAM2029 clinical program 5 completed Final results Phase 1 and 2 Open label extension clinical trials characterizing PK, PD and Fully recruited safety in Open label extension healthy subjects and Fully recruited Final results patients Open label extension -2022 2023 2024 2025 2026 2027
Slide 20: Positive results from ACROINNOVA 2
Positive results from ACROINNOVA 2 •ACROINNOVA 2 study design •ACROINNOVA 2 results ‒ 52-week, open-label safety study with further extension ‒ Increased response rate from SoC baseline with in new recruited patients* •Patient population ‒ Reinforcing long-term safety and effectiveness in ‒ New pati
Slide 21: Acromegaly symptoms decreased during treatment with CAM2029
Acromegaly symptoms decreased during treatment with CAM2029 Continued symptom improvements after switch from SoC 0,5 Overall study population Acromegaly index of severity overall score, Change from baseline (mean, 95% CI) 0 Acromegaly index of severity (AIS) The AIS overall score was calculated as -
Slide 22: CAM2029 progressing towards market with expected milestones 2025
CAM2029 progressing towards market with expected milestones 2025 Pivotal randomized placebo controlled Subcutaneous Octreotide Randomized Polycystic liver Safety and efficacy and long-term safety trials in acromegaly Efficacy in Neuroendocrine TumOrs TriAl with subcutaneous Octreotide Positive resul
Slide 23: Towards new therapy areas
23 Towards new therapy areas Donna, akromegali Josh, GEP-NET Laura, akromegali Angeliki, akromegali Melissa, akromegali Ken, akromegali • Darro, akromegali Kath, GEP-NET Simona, GEP-NET CONFIDENTIAL
Slide 24: Early-stage programs
Early-stage programs Several early-stage programs advancing Phase 1 study of CAM2056 ongoing Positive data and assessments of multiple preclinical drug candidates, including long-acting incretins 24
Slide 25: CAM2056 entered clinical development
CAM2056 entered clinical development •CAM2056 – once monthly FluidCrystal semaglutide Completed preclinical program met target profile for pharmacokinetics, pharmacodynamics (incl. weight management) and tolerability •Clinical Phase 1 study initiated Phase 1 study initiated assessing pharmacokinetic
Slide 26: Camurus expanding
Camurus expanding •New headquarter in Science Village, Lund ‒ Opened in January 2025 ‒ ~3,700m2 on the top floors of the “The Loop” ‒ Offices and state-of-the-art laboratories ‒ Sustainability profile with LEED Gold certification ‒ Capacity to grow to ~250 people Camurus AB│Rydbergs torg 4, SE-224 8
Slide 27: Positive development expected near-term
Positive development expected near-term Continued growth of Buvidal in Europe and Australia Increased market penetration of Brixadi in the US Market approvals of CAM2029 in acromegaly Clinical results for CAM2029 and CAM2056 Diversification through business development Positive financial outlook 202
Slide 28: Thank you!
Thank you! Camurus AB│Rydbergs torg 4, SE-224 84 Lund, Sweden P +46 46 286 57 30│info@camurus.com│camurus.com